SETD2-H3K36ME3: an important bridge between the environment and tumors
暂无分享,去创建一个
Fangrui Zhao | Q. Hu | Jiahui He | Tangpeng Xu | Jin Guo
[1] A. Jemal,et al. Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.
[2] Feng Yue,et al. Clinical and histopathologic characterization of SETD2-mutated colorectal cancer. , 2022, Human pathology.
[3] Mingzhu Liu,et al. Tumor Cell‐Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis , 2022, Advanced science.
[4] S. Jarmalaitė,et al. The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer , 2022, International journal of molecular sciences.
[5] I. Varela,et al. Role of SWI/SNF chromatin remodeling genes in lung cancer development. , 2022, Biochemical Society transactions.
[6] S. Armstrong,et al. SETD2 haploinsufficiency enhances germinal center-associated AICDA somatic hypermutation to drive B cell lymphomagenesis. , 2022, Cancer discovery.
[7] D. Koundal,et al. Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures , 2022, BioMed research international.
[8] Yajie Xiao,et al. Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients , 2022, Cancer cell international.
[9] Qing Li,et al. Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1–IL‐8 signaling‐mediated epithelial–mesenchymal transition in lung adenocarcinoma , 2022, Cancer science.
[10] A. Papanicolau‐Sengos,et al. DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis. , 2021, Annual review of pathology.
[11] M. Ladanyi,et al. Brief Report: Molecular characterization of peritoneal mesotheliomas. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[12] R. Gorlick,et al. Advancing therapy for osteosarcoma , 2021, Nature Reviews Clinical Oncology.
[13] Bin Zhao,et al. Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy , 2021, npj Precision Oncology.
[14] Min Liu,et al. The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis , 2021, Redox biology.
[15] Pengcheng Bu,et al. Non-coding RNA in cancer , 2021, Essays in biochemistry.
[16] U. Matulonis,et al. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[18] Bryan A. Millis,et al. The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase , 2020, Science Advances.
[19] I. Ahluwalia,et al. Revisiting the association between worldwide implementation of the MPOWER package and smoking prevalence, 2008–2017 , 2020, Tobacco Control.
[20] Jian Zhang,et al. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways. , 2020, Cancer cell.
[21] M. Ji,et al. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers , 2020, Journal of Cancer.
[22] Jingting Jiang,et al. Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma , 2020, Aging.
[23] Zhi-hua Shen,et al. [Quantitative proteomics and differential signal enrichment in nasopharyngeal carcinoma cells with or without SETD2 gene knockout]. , 2019, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
[24] P. Lu,et al. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia–mesenchymal transition during pancreatic carcinogenesis , 2019, Gut.
[25] T. Voeltzel,et al. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells , 2019, Cell proliferation.
[26] A. Pandiella,et al. Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors , 2019, PloS one.
[27] Y. Hayashi,et al. SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints , 2019, Leukemia.
[28] S. Rudzki,et al. Environmental risk factors for cancer - review paper. , 2019, Annals of agricultural and environmental medicine : AAEM.
[29] Ke Chen,et al. Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer , 2019, Medical science monitor : international medical journal of experimental and clinical research.
[30] Ming Huang,et al. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development* , 2018, Molecular & Cellular Proteomics.
[31] T. Ho,et al. Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. , 2018, Journal of proteome research.
[32] G. Giaccone,et al. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer , 2018, Oncogene.
[33] F. Grebien,et al. SETD2 in MLL-rearranged leukemia – a complex case , 2018, Molecular & cellular oncology.
[34] Voichita D. Marinescu,et al. SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma. , 2018, Cancer research.
[35] Saijuan Chen,et al. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation , 2018, Cell Research.
[36] Xin Fan,et al. SETD2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion. , 2018, Biochemical and biophysical research communications.
[37] S. Armstrong,et al. SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. , 2017, Blood.
[38] M. Esteller,et al. Lung cancer epigenetics: From knowledge to applications. , 2017, Seminars in cancer biology.
[39] J. Qin,et al. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. , 2017, The Journal of clinical investigation.
[40] Daniel Baumhoer,et al. Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma , 2017, Nature Communications.
[41] G. O'Neill,et al. Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma , 2017, Oncogenesis.
[42] D. Feldser,et al. Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma. , 2017, Cancer research.
[43] Jiejie Xu,et al. Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. , 2016, The Journal of urology.
[44] P. Gaulard,et al. Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations , 2016, Nature Communications.
[45] T. Cierpicki,et al. H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development. , 2016, Future medicinal chemistry.
[46] T. Ho,et al. Dual Chromatin and Cytoskeletal Remodeling by SETD2 , 2016, Cell.
[47] M. Ladanyi,et al. Genomic aberrations frequently alter chromatin regulatory genes in chordoma , 2016, Genes, chromosomes & cancer.
[48] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[49] Gerben Duns,et al. SETD2: an epigenetic modifier with tumor suppressor functionality , 2016, Oncotarget.
[50] James E Audia,et al. Histone Modifications and Cancer. , 2016, Cold Spring Harbor perspectives in biology.
[51] Jeffrey S. Morris,et al. The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.
[52] Swe Swe Myint,et al. SETD2 histone modifier loss in aggressive GI stromal tumours , 2015, Gut.
[53] A. Lopez‐Beltran,et al. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies , 2015, Expert review of molecular diagnostics.
[54] Karl J. Dykema,et al. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma , 2015, Oncogene.
[55] K. Shaw,et al. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. , 2015, Cancer letters.
[56] Y. Chung,et al. Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. , 2014, Human pathology.
[57] Heather L. Mulder,et al. The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes , 2014, Nature Communications.
[58] S. Armstrong,et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in pediatric acute lymphoblastic leukemia , 2014, Nature Communications.
[59] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[60] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[61] Sivan Sabato,et al. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes , 2013, Genome Biology.
[62] David T. W. Jones,et al. Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.
[63] Robert A. Martienssen,et al. RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond , 2013, Nature Reviews Genetics.
[64] Peter A. Jones,et al. A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.
[65] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[66] T. Roberts,et al. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters , 2009, BMC Cancer.
[67] F. He,et al. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. , 2008, Cellular signalling.
[68] D. Bettcher,et al. Clinical cancer control and prevention. Eliminating tobacco-induced cancers: a worldwide challenge. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] J. Licht,et al. Epigenetic regulation of normal and malignant hematopoiesis , 2007, Oncogene.
[70] C. Allis,et al. Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling. , 2007, Trends in molecular medicine.
[71] H. Erdjument-Bromage,et al. Histone demethylation by a family of JmjC domain-containing proteins , 2006, Nature.
[72] Fredrik Nyberg,et al. Contribution of environmental factors to cancer risk. , 2003, British medical bulletin.
[73] G. Prendergast,et al. Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. , 1991, Science.
[74] M. Ehrlich,et al. The 5-methylcytosine content of DNA from human tumors. , 1983, Nucleic acids research.
[75] I. Wistuba,et al. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] Zhu Chen,et al. Erratum to H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm [Cell Reports 8, (2014) 1989-2002] , 2014 .
[77] M. Goodell,et al. Hematopoietic stem cell development: an epigenetic journey. , 2014, Current topics in developmental biology.
[78] C. Roberts,et al. ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.
[79] K. Klauke. Epigenetic regulation of normal and malignant hematopoiesis , 2013 .
[80] H. Seitz,et al. ALCOHOL AND CANCER , 2007 .